Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer. 2017;17(1):65–74.
CAS PubMed Article Google Scholar
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
National Cancer Institute. Cancer stat facts: ovarian cancer. Available from: https://seer.cancer.gov/statfacts/html/ovary.html.
Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005;5(5):355–66.
CAS PubMed Article Google Scholar
Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53.
Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol. 2012;23(Suppl 10):x118–27.
Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773.
Dobzhansky T. Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura. Genetics. 1946;31(3):269–90.
CAS PubMed PubMed Central Article Google Scholar
Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84(10):1424–31.
CAS PubMed PubMed Central Article Google Scholar
Scherer WF, Syverton JT, Gey GO. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med. 1953;97(5):695–710.
CAS PubMed PubMed Central Article Google Scholar
Harrison RK. Phase II and phase III failures: 2013-2015. Nat Rev Drug Discov. 2016;15(12):817–8.
CAS PubMed Article Google Scholar
Alteri E, Guizzaro L. Be open about drug failures to speed up research. Nature. 2018;563(7731):317–9.
CAS PubMed Article Google Scholar
DiMasi JA, Reichert JM, Feldman L, Malins A. Clinical approval success rates for investigational cancer drugs. Clin Pharmacol Ther. 2013;94(3):329–35.
CAS PubMed Article Google Scholar
Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. Plos One. 2014;9(9):e103988.
PubMed PubMed Central Article CAS Google Scholar
Barnes BM, Nelson L, Tighe A, Burghel GJ, Lin IH, Desai S, et al. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. Genome Med. 2021;13(1):140.
CAS PubMed PubMed Central Article Google Scholar
Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, et al. Type-specific cell line models for type-specific ovarian cancer research. Plos One. 2013;8(9):e72162.
CAS PubMed PubMed Central Article Google Scholar
Jacob F, Nixdorf S, Hacker NF, Heinzelmann-Schwarz VA. Reliable in vitro studies require appropriate ovarian cancer cell lines. J Ovarian Res. 2014;7:60.
PubMed PubMed Central Article CAS Google Scholar
Kreuzinger C, Gamperl M, Wolf A, Heinze G, Geroldinger A, Lambrechts D, et al. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. Cancer Lett. 2015;362(2):218–28.
CAS PubMed Article Google Scholar
Kreuzinger C, von der Decken I, Wolf A, Gamperl M, Koller J, Karacs J, et al. Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer. Cancer Lett. 2019;459:1–12.
CAS PubMed Article Google Scholar
Jiang W, Ye S, Xiang L, Yang W, He T, Pei X, et al. Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1). J Ovarian Res. 2018;11(1):58.
PubMed PubMed Central Article CAS Google Scholar
De Thaye E, Van de Vijver K, Van der Meulen J, Taminau J, Wagemans G, Denys H, et al. Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma. Sci Rep. 2020;10(1):6688.
PubMed PubMed Central Article CAS Google Scholar
Yamada T, Kanda T, Mori H, Shimokawa K, Kagawa M, Shibayama Y. Establishment and characterization of a cell line (NOMH-1) originating from a human endometrioid adenocarcinoma of the ovary. J Ovarian Res. 2013;6(1):8.
PubMed PubMed Central Article Google Scholar
Akahane T, Hirasawa A, Imoto I, Okubo A, Itoh M, Nanki Y, et al. Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance. Hum Cell. 2020;33(1):272–82.
Teng PN, Bateman NW, Wang G, Litzi T, Blanton BE, Hood BL, et al. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. Hum Cell. 2017;30(3):226–36.
CAS PubMed Article Google Scholar
Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, et al. Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 1987;47(2):414–8.
Viscarra T, Buchegger K, Jofre I, Riquelme I, Zanella L, Abanto M, et al. Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line. Biol Res. 2019;52(1):13.
PubMed PubMed Central Article Google Scholar
Zhang J, Zhao J, Zhang W, Liu G, Yin D, Li J, et al. Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance. Int J Gynecol Cancer. 2012;22(9):1450–6.
Cicchillitti L, Di Michele M, Urbani A, Ferlini C, Donat MB, Scambia G, et al. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J Proteome Res. 2009;8(4):1902–12.
CAS PubMed Article Google Scholar
Golan Berman H, Chauhan P, Shalev S, Hassanain H, Parnas A, Adar S. Genomic characterization of cisplatin response uncovers priming of cisplatin-induced genes in a resistant cell line. Int J Mol Sci. 2021;22(11):5814.
Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21(4):585–91.
CAS PubMed Article Google Scholar
Li S, Zhang Z, Han L. Molecular treasures of Cancer cell lines. Trends Mol Med. 2019;25(8):657–9.
Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813–23.
CAS PubMed Article Google Scholar
Ledford H. US cancer institute to overhaul tumour cell lines. Nature. 2016;530(7591):391.
PubMed Article CAS Google Scholar
Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 2013;73(14):4372–82.
CAS PubMed PubMed Central Article Google Scholar
List of NCI-60 Human Tumor Cell Lines Available from: https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm.
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–7.
CAS PubMed PubMed Central Article Google Scholar
Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570–5.
CAS PubMed PubMed Central Article Google Scholar
Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M, et al. Integrated genomic, Epigenomic, and expression analyses of ovarian Cancer cell lines. Cell Rep. 2018;25(9):2617–33.
CAS PubMed PubMed Central Article Google Scholar
Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2012;2(2):172–89.
留言 (0)